| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/16/2009 | US20090098162 Herpes simplex virus combined subunit vaccines and methods of use thereof |
| 04/16/2009 | US20090098161 removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition and to impair Complement Factor H binding, CD55 and CD59 removal prevent the binding of Complement Factor H; Acquired Immunodeficiency Syndrome |
| 04/16/2009 | US20090098160 sialic acid is removed to enhance immune recognition and to impair Complement Factor H binding; CD55 and CD59 removal prevents the binding of Complement Factor H; Acquired Immunodeficiency Syndrome |
| 04/16/2009 | US20090098159 Cultured feline fetal tissue generated in absence of mammalian polypeptides for use as bioreactor in production of inexpensive feline vaccine |
| 04/16/2009 | US20090098158 Porcine cirocvirus type 2 (PCV2); Actinobacillus pleuropneumoniae, Haemophilus parasuis, Mycoplasma hyrhinis, Mycoplasma hyopneumoniae, Pasteurella multocida, Salmonella spp., Strepococcus suis |
| 04/16/2009 | US20090098157 Helicobacter Pylori Vaccination |
| 04/16/2009 | US20090098156 Regimens for immunisation with meningococcal conjugates |
| 04/16/2009 | US20090098155 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
| 04/16/2009 | US20090098154 Yeast-Based Vaccines As Immunotherapy |
| 04/16/2009 | US20090098153 Activation of HCV-specific T cells |
| 04/16/2009 | US20090098152 Vaccines Containing Canine Parvovirus Genetic Variants |
| 04/16/2009 | US20090098151 proteins used for eliciting an immune response in an animal to produce an antibody that binds selectively to an amyotrophic lateral sclerosis (ALS)-specific epitope, in a mixture with diluents, carriers or adjuvants |
| 04/16/2009 | US20090098150 Anti-acetylated huntingtin antibodies and uses therof |
| 04/16/2009 | US20090098149 Transgenic algae for delivering antigens to an animal |
| 04/16/2009 | US20090098148 High efficiency tissue-specific compound delivery system using streptavadin-protein a fusion protein |
| 04/16/2009 | US20090098147 Antibody fragment-polymer conjugates and uses of same |
| 04/16/2009 | US20090098146 Methods to diagnose a required regulation of trophoblast invasion |
| 04/16/2009 | US20090098145 Methods and compositions for treating ophthalmic conditions via modulation of megalin activity |
| 04/16/2009 | US20090098144 Immunogen presenting hiv gp120 v3 loop in a conformation that induces broadly neutralizing antibodies |
| 04/16/2009 | US20090098143 Vaccine production for pathogenic bird viral diseases |
| 04/16/2009 | US20090098142 Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| 04/16/2009 | US20090098141 IL-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same |
| 04/16/2009 | US20090098140 Monoclonal antibodies and their use |
| 04/16/2009 | US20090098139 Combination therapy for the treatment of neovascular disorders |
| 04/16/2009 | US20090098138 Detection of proteins from circulating neoplastic cells |
| 04/16/2009 | US20090098137 Combinations of therapeutic agents for treating cancer |
| 04/16/2009 | US20090098136 Use of tnf receptor antagonists for treating dry eye |
| 04/16/2009 | US20090098135 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| 04/16/2009 | US20090098134 Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
| 04/16/2009 | US20090098133 3-Cyano-2-[3-(2-ethoxy-phenyl)-propanoylamino]-4,7-dihydro-5H-thieno[2,3-c]pyridine-6-carboxylic acid tert-butyl ester; cell-cycle specific inducers of apoptosis in cancer cells |
| 04/16/2009 | US20090098132 Composition and method for treating lupus nephritis |
| 04/16/2009 | US20090098131 Compositions and methods for the treatment of immune related diseases |
| 04/16/2009 | US20090098130 Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| 04/16/2009 | US20090098129 Member of the TNF Ligand Family |
| 04/16/2009 | US20090098128 NPC1L1 orthologues |
| 04/16/2009 | US20090098127 Agents Capable of Downregulating an MSF-A DEPENDENT HIF-1ALPHA and Use Thereof in Cancer Treatment |
| 04/16/2009 | US20090098126 Method and kit for the detection of adenoviruses |
| 04/16/2009 | US20090098125 PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
| 04/16/2009 | US20090098124 Identification and engineering of antibodies with variant heavy chains and methods of using same |
| 04/16/2009 | US20090098123 Hcv coreceptor and methods of use thereof |
| 04/16/2009 | US20090098122 sRAGE Mimetibody, Compositions, Methods and Uses |
| 04/16/2009 | US20090098121 Monoclonal antibody fusion comprising bactericidal agent for use in targeted destruction of microorganisms; for use in health care, veterinary medicine and food processing |
| 04/16/2009 | US20090098120 Compositions and methods for the treatment of immune related diseases |
| 04/16/2009 | US20090098119 Antidotes for factor xa inhibitors and methods of using the same |
| 04/16/2009 | US20090098118 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| 04/16/2009 | US20090098117 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 04/16/2009 | US20090098116 Immunogenic compositions for induction of anti-tumor immunity |
| 04/16/2009 | US20090098115 Cell lines and animal models of HER2 expressing tumors |
| 04/16/2009 | US20090098114 ALK7 and myostatin inhibitors and uses thereof |
| 04/16/2009 | US20090098113 Activin-ActRIIa antagonists and uses for promoting bone growth |
| 04/16/2009 | US20090098112 Novel antibodies |
| 04/16/2009 | US20090098111 Methods for modulating checkpoint activation through TopBP1 |
| 04/16/2009 | US20090098110 Injectable forms of solid-forming crosslinked bioelastic biopolymers for local drug delivery |
| 04/16/2009 | US20090098109 Compositions and Methods For Enhancing Neuronal Plasticity and Regeneration |
| 04/16/2009 | US20090098108 means of delivering the GLP-1 peptide in a sustained manner; obesity related disorders |
| 04/16/2009 | US20090098107 Method of Detecting Relative Risk for the Onset of Atopic Dermatitis by Gene Single Nucleotide Polymorphism Analysis |
| 04/16/2009 | US20090098106 PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-kB ACTIVITY |
| 04/16/2009 | US20090098105 Treatment of neurodegenerative diseases by the use of scd4 inhibitors |
| 04/16/2009 | US20090098083 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| 04/16/2009 | US20090098063 Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| 04/16/2009 | US20090098054 Methods and compositions relating to promoter regulation by muc1 and klf proteins |
| 04/16/2009 | US20090098046 Combination Cancer Therapy with Anti-PSMA Antibodies |
| 04/16/2009 | US20090098045 Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| 04/16/2009 | CA2704178A1 Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis |
| 04/16/2009 | CA2702400A1 Mite antigenic rice |
| 04/16/2009 | CA2702314A1 Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors |
| 04/16/2009 | CA2702217A1 Modulation of sirp.alpha. - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| 04/16/2009 | CA2702186A1 Medicaments and methods for treating mesothelioma |
| 04/16/2009 | CA2702155A1 Botulinum neurotoxin vaccine |
| 04/16/2009 | CA2702154A1 A method of transfection and compositions therefor |
| 04/16/2009 | CA2701948A1 Hiv preventive vaccine based on hiv specific antibodies |
| 04/16/2009 | CA2701793A1 Monoclonal antibody |
| 04/16/2009 | CA2701790A1 Humanized antibody |
| 04/16/2009 | CA2701788A1 Humanized antibody |
| 04/16/2009 | CA2701727A1 Cytomegalovirus vaccines and methods of production |
| 04/16/2009 | CA2701189A1 Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| 04/16/2009 | CA2700937A1 Method of eliciting an immune response against pandemic influenza virus |
| 04/16/2009 | CA2700812A1 Immune stimulatory oligonucleotide analogs containing modified sugar moieties |
| 04/16/2009 | CA2698326A1 Antibody targeting osteoclast-related protein siglec-15 |
| 04/16/2009 | CA2696772A1 Composition for treating prostate cancer (pca) |
| 04/16/2009 | CA2696768A1 Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| 04/15/2009 | EP2048505A2 Method for early recognition of the seroconversion of an antibody to hepatitis C |
| 04/15/2009 | EP2048237A1 Replication deficient Influenza virus for the expression of heterologous sequences |
| 04/15/2009 | EP2048230A1 Cell death inducer |
| 04/15/2009 | EP2048163A1 Antihuman alpha- 9 integrin antibody and use of the same |
| 04/15/2009 | EP2048162A1 Novel monoclonal antibody and use of the same |
| 04/15/2009 | EP2048160A1 Tumor antigen based on products of the tumor suppressor gene WT1 |
| 04/15/2009 | EP2048157A1 Polynucleotide encoding the rg1 polypeptide |
| 04/15/2009 | EP2047863A1 Preventive or remedy for inflammatory disease |
| 04/15/2009 | EP2047862A1 Remedy for renal disease |
| 04/15/2009 | EP2047861A1 Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications |
| 04/15/2009 | EP2047860A1 Phamaceutical compositons comprosing actinomycete glycerol acyl derivatives antigens, their process of extractin, and their use against tuberculosis. |
| 04/15/2009 | EP2047256A1 A method for the in vitro screening of anti-cancer compounds that inhibits sk3 activity, and said anti-cancer compounds |
| 04/15/2009 | EP2046836A1 Antibody specifically binding to dr5 and composition for preventing or treating cancers comprising the same |
| 04/15/2009 | EP2046835A2 Antibodies to il-17a |
| 04/15/2009 | EP2046834A1 Monoclonal antibodies against stromal derived factor-1 (sdf-1) |
| 04/15/2009 | EP2046823A1 Post-translationally modified neurotrophins |
| 04/15/2009 | EP2046812A1 A cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide |
| 04/15/2009 | EP2046807A2 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
| 04/15/2009 | EP2046385A2 Composition for modulating the expression of cell adhesion molecules |